Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds
Executive Summary
Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased
You may also be interested in...
Post-Market Studies: Even With New Powers, FDA Relies On Firms’ Judgments
BOSTON - When it comes to setting deadlines for completing post-marketing safety studies, industry has the expertise, Office of New Drugs Deputy Director Sandra Kweder told the Drug Information Association meeting on June 24
Post-Market Studies: Even With New Powers, FDA Relies On Firms’ Judgments
BOSTON - When it comes to setting deadlines for completing post-marketing safety studies, industry has the expertise, Office of New Drugs Deputy Director Sandra Kweder told the Drug Information Association meeting on June 24
FDA’s Sentinel Safety Surveillance Could Ease Phase IV Study Burden
FDA recognizes its Sentinel post-market safety surveillance project could help answer some questions that typically would be explored in Phase IV studies